Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

L-742728 selected by Merck & Co. for further evaluation

April 12, 1996

Virend entering phase III

April 5, 1996

Nabi foresees phase I/II trials on CMV NeutraGAM

April 5, 1996

Lidakol formulations receive patent protection

April 5, 1996

BILD-1351 for HSV infection

April 5, 1996

BMS discloses novel cephalosporins

April 5, 1996

MBI-10 antibiotics effective against resistant staphylococci

April 5, 1996

Glaxo Wellcome, Quidel collaborate on flu management

March 15, 1996

Lidakol clinical trial update

March 15, 1996

Antiviral drugs from Glaxo Wellcome

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 15, 2025.
ASGCT 2025: Gene and cell therapies transform metabolic diseases
BioWorld Science
Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
Abbott studies show CGM users have fewer hospitalizations
BioWorld MedTech
A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces hospitalizations in people with type 1 diabetes and...
Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug
BioWorld
Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene...